Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lora Inclan"'
Autor:
Jonathan H. Schatz, Jose M. Guillen-Rodriguez, Lora Inclan, Faiz Anwer, Daniel O. Persky, Xavier Rivera, Kara Heard, Abhijeet Kumar, Soham D. Puvvada, Daruka Mahadevan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:58-64
Background Mantle-cell lymphoma (MCL) and indolent non-Hodgkin lymphoma (iNHL) are incurable heterogeneous diseases characterized by relapse. There is a need for newer treatments in MCL and iNHL, especially in the relapsed/refractory (R/R) setting. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82a6c60a15e56b922a12895198981306
https://doi.org/10.1016/j.clml.2017.09.001
https://doi.org/10.1016/j.clml.2017.09.001
Autor:
Soham D. Puvvada, Kara Heard, Xavier Rivera, Daniel O. Persky, Jonathan H. Schatz, Lora Inclan, Jose M. Guillen-Rodriguez, Monika Schmelz
Publikováno v:
Oncology. 93(6)
Objective: Aggressive lymphomas (aNHL) including diffuse large B-cell lymphoma (DLBCL) have poor outcomes in relapsed refractory patients. Prior studies have demonstrated that loss of major histocompatibility complex class II (MHCII) expression in DL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64e683ec3e04845b1db8f2050c598c1a
https://pubmed.ncbi.nlm.nih.gov/28869931
https://pubmed.ncbi.nlm.nih.gov/28869931
Autor:
Abhijeet Kumar, Melissa Beelen, Benjamin Suttle, Gary K. Schwartz, Daniel O. Persky, Jennifer E Amengual, Patricia Robles-Medina, Lora Inclan, Shahnaz Singh-Kandah
Publikováno v:
Cancer Research. 79:CT028-CT028
TAZ, a selective, oral EZH2 inhibitor, is in the phase 2 clinical investigation stage for the treatment of advanced solid tumors (AdvST) and B-cell non-Hodgkin lymphoma (NHL). Drug-drug interaction (DDI) potential of TAZ was investigated in study EZH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6d871dac4530817442c71da021c660c
https://doi.org/10.1158/1538-7445.am2019-ct028
https://doi.org/10.1158/1538-7445.am2019-ct028
Autor:
Abhijeet Kumar, Jose Guillen-Rodriguez, Jonathan H. Schatz, Lora Inclan, Alfonso E Ayala, Xavier Rivera, Srinath Sundararajan, Faiz Anwer, Daruka Mahadevan, Daniel O. Persky, Soham D. Puvvada
Publikováno v:
Blood. 128:1790-1790
Background: Mantle cell lymphoma (MCL) is characterized by initial sensitivity to both chemotherapy and radiation but also by an invariable relapse and eventual resistance to treatment. Bortezomib (Velcade) is a proteasome inhibitor and is approved a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa792b3b1ccf8c9a221c10d62a6dc647
https://doi.org/10.1182/blood.v128.22.1790.1790
https://doi.org/10.1182/blood.v128.22.1790.1790
Autor:
Glenn J. Shamdas, Earl A. Surwit, Kenneth D. Hatch, Scott M. Lippman, David S. Alberts, Joel M. Childers, Lora Inclan, Manuel R. Modiano, Alton V. Hallum
Publikováno v:
Gynecologic Oncology. 56:382-386
The combination of 13-cis-retinoic acid (13-cRA) and interferon (IFN)-alpha 2a has been reported to be highly active in previously untreated squamous carcinoma of the cervix. In this phase II study, 13-cRA was given at a dose of 1 mg/kg/day and IFN-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::813dddc85e682f32f70a5261a281a177
https://doi.org/10.1006/gyno.1995.1067
https://doi.org/10.1006/gyno.1995.1067
Autor:
Jonathan H. Schatz, Lora Inclan, Ellen M. Chase, Jose Guillen, Denise J. Roe, Soham D. Puvvada, Thomas P. Miller, Daniel O. Persky
Publikováno v:
Blood. 122:4404-4404
Background Radioimmunoconjugates are effective treatment in relapsed/refractory follicular lymphoma (FL) when used as single agents, and can result in effective disease control (Kaminski et al, NEJM 1993; Witzig, JCO 2002). When used as consolidative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cbbf28d88e2c1e9d3c1fc4a8341f22d
https://doi.org/10.1182/blood.v122.21.4404.4404
https://doi.org/10.1182/blood.v122.21.4404.4404